Skip to main content

Chemical and Pharmacological Chaperones: Application for Recombinant Protein Production and Protein Folding Diseases

Buy Article:

$63.00 plus tax (Refund Policy)

Abstract:

Since protein function depends on folding, successful development of active pharmaceutical proteins requires in vitro production of functional, properly folded proteins. In vitro protein folding and hence production can be assisted by co-solvents, including osmolytes and arginine. Osmolytes accumulate in the cytoplasm to raise the osmotic pressure against environmental water stresses, resulting in stabilization of proteins. They have shown to enhance in vitro and in vivo protein folding and suppress in vivo protein aggregation, thus called “chemical chaperones”. Requirement of high concentrations, however, eliminates possible applications of chemical chaperones to rescue in vivo misfolded proteins that cause various diseases. More specific ligands can serve a similar function at much lower concentrations and are called “pharmacological chaperones”. We will review here the applications of chemical chaperones for biotechnology product development and of pharmacological chaperones for in vivo protein folding, and the mechanism of their effects on protein folding. A specific case we review here is the mechanism of action of the polar amino acid arginine, which has been widely used in vitro as a chemical chaperone to assist protein folding and suppress aggregation.





Keywords: Anifinsen's principle; Chaperones; Chemical chaperone; Cytoplasmic Soluble Expression; Dialysis; E. coli; Escherichia coli; HETEROLOGOUS; Immunofluorescence; Osmolytes; Periplasmic Expression; Proline; Protein; Sarcosine; aggregate formation; antibodies; antitrypsin; biogenesis; biopharmaceutical development; cell membranes; cells; chaperones; column chromatography; compatible solutes; cystic fibrosis; cytoplasm; dialysis; dilution; enzymes; equilibrium; globular proteins; glycerol; glycosylation; green fluorescent protein (GFP); halophile; halophilic bacteria; halophilic organisms; high affinity; hydration; hydrophobic; inclusion bodies; insoluble proteins; ionic; kinetics; lysozyme; mutants; nephrogenic diabetes; non-osmolyte arginine; osmolyte; osmolytes; osmotic pressure; pharmaceutical drugs; pharmacological chaperon; phenyl butyric acid (PBA); phenylalanine; polar natural; proteasomal degradation; protein solution; pulmonary tissues; racemization activities; recombinant protein; ribosome; severe acute syndrome (SARS); solubility; solubilization; solvent; thermodynamic; thermodynamic stability; urine; vasopressin V2

Document Type: Research Article

DOI: https://doi.org/10.2174/092986711793979698

Publication date: 2011-01-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more